Pfizer Receives FDA Fast Track Designation For Tafamidis

The U.S. Food and Drug Administration has granted fast track designation to Pfizer’s tafamidis, the company’s investigational treatment for transthyretin cardiomyopathy (TTR-CM), a rare, universally fatal disease associated with progressive heart failure. There are currently approximately 1,000 diagnosed patients with TTR-CM worldwide, although the disease is believed to be significantly underdiagnosed

Currently in phase 3 clinical development, tafamidis is being evaluated for its potential to reduce mortality and cardiovascular-related hospitalizations. The ATTR-ACT study is fully enrolled and is anticipated to be completed in the first half of 2018.

Leave a Comment